The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells
Abstract
Objective: Tofacitinib (CP‐690,550) is a novel JAK inhibitor that is currently in clinical trials for the treatment of rheumatoid arthritis (RA). The aim of this study was to examine the effects of tofacitinib in vitro and in vivo in RA, in order to elucidate the role of JAK in the disease process. Methods: CD4+ T cells, CD14+ monocytes, and synovial fibroblasts (SFs) were purified from the synovium and peripheral blood of patients with RA and were evaluated for the effect of tofacitinib on cytokine production and cell proliferation. For in vivo analysis, synovium and cartilage samples obtained from patients with RA were implanted in immunodeficient mice (SCID‐HuRAg mice), and tofacitinib was administered via an osmotic minipump. Results: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin‐17 (IL‐17) and interferon‐γ (IFNγ) in a dose‐dependent manner, affecting both proliferation and transcription, but had no effect on IL‐6 and IL‐8 production. Tofacitinib did not affect IL‐6 and IL‐8 production by RASFs and CD14+ monocytes. However, conditioned medium from CD4+ T cells cultured with tofacitinib inhibited IL‐6 production by RASFs and IL‐8 production by CD14+ monocytes. Treatment of SCID‐HuRAg mice with tofacitinib decreased serum levels of human IL‐6 and IL‐8 and markedly suppressed invasion of synovial tissue into cartilage. Conclusion: Tofacitinib directly suppressed the production of IL‐17 and IFNγ and the proliferation of CD4+ T cells, resulting in inhibition of IL‐6 production by RASFs and IL‐8 production by CD14+ cells and decreased cartilage destruction. In CD4+ T cells, presumably Th1 and Th17 cells, JAK plays a crucial role in RA synovitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Cited by
Pathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions
Komatsu, N., & Takayanagi, H. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00793-5 · Cited by 527
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Self-citationJanus kinase inhibitors in autoimmune diseases
O'Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202576 · Cited by 453
Self-citationTofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 435
Metadata
- Authors
- Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., Yoshimatsu, H., & Tanaka, Y.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-05-25
- Volume
- 64
- Issue
- 6
- Pages
- 1790-1798
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2095522674
- Cited by
- 233
- References
- 3
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells. https://app.cochat.ai/papers/10.1002/art.34329
- The paper
- Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., Yoshimatsu, H., & Tanaka, Y. (2012). The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells. Arthritis & Rheumatism. https://doi.org/10.1002/art.34329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.